Q2 2022

Filed Aug 12, 2022 · 10-Q · 43 days after period end · 0001640334-22-001752

Q2 2022 · 10-Q

Revenue

$0.00

−100.0% vs Q2 2021

Net Income

-$4.00M

N/M vs Q2 2021

EPS, diluted—

Gross Profit$0−100.0%

Operating Income-$3,996,432N/M

Same quarter

Metric	Q2 2022	Q2 2021	Q2 2020	Q2 2019
Revenue	$0.00	$500.00K	$0.00	$0.00
Net Income	-$4.00M	-$794.69K	-$63.70K	-$50.82K
EPS Diluted	—	-$0.02	$0.00	$0.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR